Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: An international follow-up study

Gastroenterology

Volumn 147, Issue 6, 2014, Pages 1338-1349.e5

  Lammers, Willem J ^a   Van Buuren, Henk R ^a   Hirschfield, Gideon M ^b   Janssen, Harry L A ^c   Invernizzi, Pietro ^d   Mason, Andrew L ^e   Ponsioen, Cyriel Y ^f   Floreani, Annarosa ^g   Corpechot, Christophe ^h   Mayo, Marlyn J ⁱ   Battezzati, Pier M ^j   Parés, Albert ^k   Nevens, Frederik ^l   Burroughs, Andrew K ^m   Kowdley, Kris V ⁿ   Trivedi, Palak J ^b   Kumagi, Teru ^c,o   Cheung, Angela ^c   Lleo, Ana ^d   Imam, Mohamad H ^p   Boonstra, Kirsten ^f   Cazzagon, Nora ^g   Franceschet, Irene ^g   Poupon, Raoul ^h   Caballeria, Llorenç ^k   Pieri, Giulia ^m   Kanwar, Pushpjeet S ⁿ   Lindor, Keith D ^p,q   Hansen, Bettina E ^a   more..

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c TORONTO WESTERN HOSPITAL   (Canada)

^d HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^e UNIVERSITY OF ALBERTA   (Canada)

^f ACADEMIC MEDICAL CENTER   (Netherlands)

^g UNIVERSITY OF PADOVA   (Italy)

^h HÔPITAL SAINT ANTOINE   (France)

ⁱ UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^j UNIVERSITY OF MILAN   (Italy)

^k UNIVERSITY OF BARCELONA   (Spain)

^l UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^m ROYAL FREE HOSPITAL   (United Kingdom)

ⁿ VIRGINIA MASON MEDICAL CENTER   (United States)

^o EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^p MAYO CLINIC   (United States)

^q ARIZONA STATE UNIVERSITY   (United States)

more..

Author keywords

Autoimmune Liver Disease; Biomarker; New Therapies; Response To Treatment

Indexed keywords

ALBUMIN; ALKALINE PHOSPHATASE; BILIRUBIN; URSODEOXYCHOLIC ACID; BIOLOGICAL MARKER; CHOLAGOGUE;

ADULT; ALBUMIN BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BILIRUBIN BLOOD LEVEL; CAUSE OF DEATH; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE COURSE; EUROPEAN; FEMALE; FOLLOW UP; HIGH RISK POPULATION; HISTOPATHOLOGY; HUMAN; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; NORTH AMERICAN; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PRIMARY BILIARY CIRRHOSIS; PROGNOSIS; SURGICAL RISK; SURVIVAL RATE; SURVIVAL TIME; AGED; BLOOD; LIVER CIRRHOSIS, BILIARY; MEDICAL EDUCATION; META ANALYSIS; METABOLISM; MIDDLE AGED; MORTALITY; RISK FACTOR; STATISTICS AND NUMERICAL DATA; SURVIVAL;

ADULT; AGED; ALKALINE PHOSPHATASE; BILIRUBIN; BIOMARKERS; CHOLAGOGUES AND CHOLERETICS; EDUCATION, MEDICAL, CONTINUING; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIVER CIRRHOSIS, BILIARY; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RISK FACTORS; SURVIVAL ANALYSIS; URSODEOXYCHOLIC ACID;

EID: 84911199789     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2014.08.029     Document Type: Article

References (34)

1. M.M. Kaplan, and M.E. Gershwin Primary biliary cirrhosis N Engl J Med 353 2005 1261 1273
2. K.D. Lindor, M.E. Gershwin, and R. Poupon Primary biliary cirrhosis Hepatology 50 2009 291 308
3. European Association for the Study of the Liver EASL clinical practice guidelines: management of cholestatic liver diseases J Hepatol 51 2009 237 267
4. A. Pares, L. Caballeria, and J. Rodes Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid Gastroenterology 130 2006 715 720
5. C. Corpechot, L. Abenavoli, and N. Rabahi Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis Hepatology 48 2008 871 877
6. E.M. Kuiper, B.E. Hansen, and R.A. de Vries Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid Gastroenterology 136 2009 1281 1287
7. T. Kumagi, M. Guindi, and S.E. Fischer Baseline ductopenia and treatment response predict long-term histological progression in primary biliary cirrhosis Am J Gastroenterol 105 2010 2186 2194
8. C. Corpechot, O. Chazouilleres, and R. Poupon Early primary biliary cirrhosis: biochemical response to treatment and prediction of long-term outcome J Hepatol 55 2011 1361 1367
9. R.E. Poupon, R. Poupon, and B. Balkau Ursodiol for the long-term treatment of primary biliary cirrhosis. The UDCA-PBC Study Group N Engl J Med 330 1994 1342 1347
10. J.M. Shapiro, H. Smith, and F. Schaffner Serum bilirubin: a prognostic factor in primary biliary cirrhosis Gut 20 1979 137 140
11. A.M. Bonnand, E.J. Heathcote, and K.D. Lindor Clinical significance of serum bilirubin levels under ursodeoxycholic acid therapy in patients with primary biliary cirrhosis Hepatology 29 1999 39 43
12. P. Krzeski, W. Zych, and E. Kraszewska Is serum bilirubin concentration the only valid prognostic marker in primary biliary cirrhosis? Hepatology 30 1999 865 869
13. C.G. Child, and J.G. Turcotte Surgery and portal hypertension Major Probl Clin Surg 1 1964 1 85
14. R.N. Pugh, I.M. Murray-Lyon, and J.L. Dawson Transection of the oesophagus for bleeding oesophageal varices Br J Surg 60 1973 646 649
15. P.S. Kamath, R.H. Wiesner, and M. Malinchoc A model to predict survival in patients with end-stage liver disease Hepatology 33 2001 464 470
16. E.R. Dickson, P.M. Grambsch, and T.R. Fleming Prognosis in primary biliary cirrhosis: model for decision making Hepatology 10 1989 1 7
17. T.W. Warnes Alkaline phosphatase Gut 13 1972 926 937
18. P. Angulo, K.D. Lindor, and T.M. Therneau Utilization of the Mayo risk score in patients with primary biliary cirrhosis receiving ursodeoxycholic acid Liver 19 1999 115 121
19. N. Momah, M.G. Silveira, and R. Jorgensen Optimizing biochemical markers as endpoints for clinical trials in primary biliary cirrhosis Liver Int 32 2012 790 795
20. J. Ludwig, E.R. Dickson, and G.S. McDonald Staging of chronic nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis) Virchows Arch A Pathol Anat Histol 379 1978 103 112
21. P. Scheuer Primary biliary cirrhosis Proc R Soc Med 60 1967 1257 1260
22. P.C. ter Borg, S.W. Schalm, and B.E. Hansen Prognosis of ursodeoxycholic Acid-treated patients with primary biliary cirrhosis. Results of a 10-yr cohort study involving 297 patients Am J Gastroenterol 101 2006 2044 2050
23. M. Carbone, G.F. Mells, and G. Pells Sex and age are determinants of the clinical phenotype of primary biliary cirrhosis and response to ursodeoxycholic acid Gastroenterology 144 2013 560 569.e7 quiz e13-14
24. Phase 3 study of obeticholic acid in patients with primary biliary cirrhosis. http://clinicaltrials.gov/ct2/show/NCT01473524.
25. T.R. Fleming, and J.H. Powers Biomarkers and surrogate endpoints in clinical trials Stat Med 31 2012 2973 2984
26. T.R. Fleming Surrogate endpoints and FDA's accelerated approval process Health Aff (Millwood) 24 2005 67 78
27. J. Goulis, G. Leandro, and A.K. Burroughs Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: a meta-analysis Lancet 354 1999 1053 1060
28. J.S. Rudic, G. Poropat, and M.N. Krstic Ursodeoxycholic acid for primary biliary cirrhosis Cochrane Database Syst Rev 12 2012 CD000551
29. J. Shi, C. Wu, and Y. Lin Long-term effects of mid-dose ursodeoxycholic acid in primary biliary cirrhosis: a meta-analysis of randomized controlled trials Am J Gastroenterol 101 2006 1529 1538
30. R.E. Poupon, K.D. Lindor, and K. Cauch-Dudek Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis Gastroenterology 113 1997 884 890
31. C. Corpechot, F. Carrat, and A. Bahr The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis Gastroenterology 128 2005 297 303
32. D.C. Rockey, S.H. Caldwell, and Z.D. Goodman Liver biopsy Hepatology 49 2009 1017 1044
33. C. Corpechot, F. Carrat, and A. Poujol-Robert Noninvasive elastography-based assessment of liver fibrosis progression and prognosis in primary biliary cirrhosis Hepatology 56 2012 198 208
34. N. Azemoto, T. Kumagi, and M. Abe Biochemical response to ursodeoxycholic acid predicts long-term outcome in Japanese patients with primary biliary cirrhosis Hepatol Res 41 2011 310 317